Do you want to read an article? Please log in or register.
MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC
Lung, Respiratory and Thoracic Cancer
ELCC 2025
Related content
Lung, Respiratory and Thoracic Cancer
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
Ann Oncol
Felip E, Cho BC, Gutiérrez V, Alip A, Besse B, Lu S, Spira AI, Girard N, Califano R, Gadgeel SM, Yang JC, Yamamoto S, Azuma K, Kim YJ, Lee KH, Danchaivijitr P, Ferreira CG, Cheng Y, Sendur MAN, Chang GC, Wang CC, Prabhash K, Shinno Y, Stroyakovskiy D, Paz-Ares L, Rodriguez-Cid JR, Martin C, Campelo MRG, Hayashi H, Nguyen D, Tomasini P, Gottfried M, Dooms C, Passaro A, Schuler M, Gelatti ACZ, Owen S, Perdrizet K, Ou SI, Curtin JC, Zhang J, Gormley M, Sun T, Panchal A, Ennis M, Fennema E, Daksh M, Sethi S, Bauml JM, Lee SH
doi: 10.1016/j.annonc.2024.05.541
ESMO 2024
Lung, Respiratory and Thoracic Cancer
MARIPOSA: Amivantamab plus lazertinib reduced the incidence of acquired MET and EGFR resistance alterations versus osimertinib in patients with NSCLC
SPECIAL REPORT
Lung, Respiratory and Thoracic Cancer
Navigating the Evolving Treatment Paradigm for Advanced EGFR-mutated NSCLC
ESMO 2024
Lung, Respiratory and Thoracic Cancer
MARIPOSA-2: OS data continued to favor amivantamab plus chemotherapy over chemotherapy alone in patients with EGFR-mutated NSCLC
ELCC 2025
Lung, Respiratory and Thoracic Cancer
LAURA: Improved trend for OS benefit with osimertinib versus placebo in patients with unresectable stage III EGFR-mutant NSCLC
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Lung Cancer
Tozuka T, Noro R, Mizutani H, Kurimoto F, Hakozaki T, Hisakane K, Naito T, Takahashi S, Taniuchi N, Yajima C, Hosomi Y, Hirose T, Minegishi Y, Okano T, Kamio K, Yamaguchi T, Seike M, East Japan Chesters Group
doi: 10.1016/j.lungcan.2024.107540
Lung, Respiratory and Thoracic Cancer
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
Lancet Oncol
Wu YL, Guarneri V, Voon PJ, Lim BK, Yang JJ, Wislez M, Huang C, Liam CK, Mazieres J, Tho LM, Hayashi H, Nhung NV, Chia PL, de Marinis F, Raskin J, Zhou Q, Finocchiaro G, Le AT, Wang J, Dooms C, Kato T, Nadal E, Hin HS, Smit EF, Wermke M, Tan D, Morise M, O'Brate A, Adrian S, Pfeiffer BM, Stroh C, Juraeva D, Strotmann R, Goteti K, Berghoff K, Ellers-Lenz B, Karachaliou N, Le X, Kim TM, INSIGHT 2 investigators
doi: 10.1016/S1470-2045(24)00270-5
ELCC 2025
Lung, Respiratory and Thoracic Cancer
SAVANNAH: Savolitinib plus osimertinib shows high response rates in EGFR-mutant NSCLC with MET overexpression and/or amplification post-osimertinib
SABCS 2024
Breast Cancer